Genelux Corporation Expands Board of Directors, Appointing Dennis Fenton, Former Amgen Executive
SAN DIEGO, Jan. 24, 2011 /PRNewswire/ -- Genelux Corporation, a privately held, clinical stage biopharmaceutical company developing diagnostic and therapeutic solutions for cancer and inflammatory diseases, today announced the appointment of Dr. Dennis Fenton, long-time Amgen executive, to the company's Board of Directors. Dr. Fenton's appointment expands the Genelux Corporation board to 5 members.
"As someone who helped to build one of the world's most successful pharmaceutical companies from the ground up, Dr. Fenton has a wealth of experience and attributes that will enable him to make a tremendous contribution to the Genelux Board," said Aladar A. Szalay, Founder, Chairman and Chief Executive Officer. "He brings to this Directorship incredible professional breadth and depth. A research scientist by training, Dr. Fenton worked in and led nearly every part of Amgen as it developed, building the most admired biotechnology manufacturing operation in the world. I am honored to welcome Dr. Fenton to the Genelux Board as our second outside Director".
Dr. Fenton, age 59, retired in December 2007 after 26 years with Amgen, where he last served as Executive Vice President of Operations. He was one Amgen's first employees, joining the company in 1982 during its first 12 months. Starting as a Research Scientist, he held positions of increasing responsibility, including Vice President of Research, Senior Vice President of Sales and Marketing, Senior Vice President of Operations and was Amgen's first Executive Vice President.
Prior to his tenure at Amgen, Dr. Fenton worked for Pfizer Central research in New Product Development from 1977 until 1981. Since his retirement from Amgen in 2008, he has been an independent consultant and a member of several boards including Amira, Kythera, CytomX, Xenoport, Genzyme, Rutgers University, the Keck Graduate Institute and the Biotechnology Institute. Dr. Fenton holds a PhD in Microbiology